A composition comprising: at least one selective ± 2 adrenergic receptor agonist selected from the group consisting of guanabenz, guanfacine, alpha-methyl DOPA (methydopamine), amphetamine, methylphenidate, lofexidine, moxonidine, dexmedetomidine, mivazerol, and (2-imidazolin-2-ylamino) quinoxaline derivatives, which derivates are formed with an acidic group other than tartrate and a dermatologically acceptable carrier, for use in treating cutaneous flushing in an individual, wherein the composition is to be administered to said individual via topical dermatological application in an amount sufficient to prevent, reduce, ameliorate or inhibit, cutaneous flushing.
